Table: Santen Pharm -6-MTH group results (IFRS)
06/11/2020 06:00
Nov 6 (Reuters)-
Santen Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Sep 30, 2020 Sep 30, 2019 Mar 31, 2021
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 118.91 118.78 235.00
(+0.1 pct) (+3.9 pct) (-2.7 pct)
Operating 18.69 19.01 35.00
(-1.7 pct) (-8.7 pct) (+4.4 pct)
Pretax 18.35 18.41 34.00
(-0.3 pct) (-7.0 pct) (+5.9 pct)
Net 13.81 13.15
(+5.1 pct) (-8.6 pct)
EPS Basic 34.58 yen 32.94 yen 58.35 yen
EPS Diluted 34.50 yen 32.85 yen
Ann Div 27.00 yen 28.00 yen
-Q2 Div 14.00 yen 13.00 yen
-Q4 Div 14.00 yen 14.00 yen
NOTE - Santen Pharmaceutical Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T